---
title: Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
date: '2023-10-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37861218/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231020180750&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Tarlatamab, administered as a 10-mg dose every 2 weeks,
  showed antitumor activity with durable objective responses and promising survival
  outcomes in patients with previously treated small-cell lung cancer. No new safety
  signals were identified. (Funded by Amgen; DeLLphi-301 ClinicalTrials.gov number,
  ...'
disable_comments: true
---
CONCLUSIONS: Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. No new safety signals were identified. (Funded by Amgen; DeLLphi-301 ClinicalTrials.gov number, ...